Will Battershill and Hollie Wheat from Delta Hat discuss key insights into HTA decision-making from ISPOR Europe. Will explores the hot topic of incorporating patient and carer perspectives into decision-making, whilst Hollie dives into the use of surrogate endpoint evaluation in HTA decision-making.
Discover our tailored health economics training for Pharma and Medtech teams. Delivered by experts, it combines practical insights with real-world experience.
Challenges for orphan medicines entering the European market – Part 3: Economic evidence development
Challenges for orphan medicines entering the European market – Part 2: Clinical evidence development
Are you unsure about some of the terminology used by specialists who are preparing your evidence dossier? Here our experts answer some of the most frequently asked questions about systematic literature reviews and network meta-analysis.
What is the EU Joint Clinical Assessment (JCA) and what does it mean for market access and reimbursment in Euorpe?
Alex Hodkinson recently joined Mtech Access as Consultant – Statistician in our evidence synthesis team. In this interview, we learn about his career to date and what inspired him to join Mtech Access. Alex also shares some of his experiences since joining the team.
Louise Maddison (Senior Consultant – Global Market Access, Mtech Access) explores the evolving market access landscape for AI-enabled Medtech, with a particular focus on the key European markets of France, Germany and the UK.